PTK2 and urinary bladder cancer: The treatment regimen of 2 h per day was chosen to align with clinical practice, where drugs used for intravesical treatment of bladder cancer are typically retained in the bladder for 2 h before voiding.56 None of the FAK inhibitors tested (the most effective concentrations were 10 μM PND-1186, 100 μM PF-573228 and 100 μM defactinib) caused a statistically significant decrease in the viability of differentiated urothelial cells after 3 days of treatment.